Cost-effectiveness of a specialized oral nutritional supplementation for malnourished older adult patients in Spain
Resumen: Malnutrition has been related to prolonged hospital stays, and to increases in readmission and mortality rates. In the NOURISH (Nutrition effect On Unplanned Readmissions and Survival in Hospitalized patients) study, administering a high protein oral nutritional supplement (ONS) containing beta-hydroxy-beta-methylbutyrate (HP-HMB) to hospitalised older adult patients led to a significant improvement in survival compared with a placebo treatment. The aim of this study was to determine whether HP-HMB would be cost-effective in Spain. We performed a cost-effectiveness analysis from the perspective of the Spanish National Health System using time horizons of 90 days, 180 days, 1 year, 2 years, 5 years and lifetime. The difference in cost between patients treated with HP-HMB and placebo was €332.75. With the 90 days time horizon, the difference in life years gained (LYG) between both groups was 0.0096, resulting in an incremental cost-effectiveness ratio (ICER) of €34, 700.62/LYG.With time horizons of 180 days, 1 year, 2 years, 5 years and lifetime, the respective ICERs were €13, 711.68, €3377.96, €2253.32, €1127.34 and €563.84/LYG. This analysis suggests that administering HP-HMB to older adult patients admitted to Spanish hospitals during hospitalisation and after discharge could be a cost-effective intervention that would improve survival with a reduced marginal cost.
Idioma: Inglés
DOI: 10.3390/nu10020246
Año: 2018
Publicado en: Nutrients 10, 2 (2018), 246 [11 pp]
ISSN: 2072-6643

Originalmente disponible en: Texto completo de la revista

Factor impacto JCR: 4.171 (2018)
Categ. JCR: NUTRITION & DIETETICS rank: 16 / 86 = 0.186 (2018) - Q1 - T1
Factor impacto SCIMAGO: 1.493 - Nutrition and Dietetics (Q1) - Food Science (Q1)

Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.


Exportado de SIDERAL (2020-01-17-21:31:30)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2018-05-08, última modificación el 2020-01-17


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)